AbCellera And Lilly Expand Collaboration To Develop Antibody Medicines
AbCellera And Lilly Expand Collaboration To Develop Antibody Medicines
AbCellera (NASDAQ:ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration established in March 2020, which included eight de novo programs for targets selected by Lilly and an exclusive license to AbCellera's COVID-19 antibody program.
AbCellera（納斯達克：ABCL）今日宣佈，已經擴大了與Eli Lilly and Company（Lilly）現有的合作，以發現用於免疫學、心血管疾病和神經科學計劃的治療性抗體。該擴展建立在自2020年3月建立的成功研究合作的基礎之上，該合作包括Lilly選定的八個全新計劃和AbCellera的COVID-19抗體計劃的獨家許可證。
AbCellera has advanced all eight programs under the original agreement, and the licensed program resulted in emergency use authorization by the U.S. Food and Drug Administration for two COVID-19 antibody therapies co-developed by the companies.
AbCellera已經推進了原始協議下的所有八個計劃，並且許可計劃通過該公司共同開發的兩種COVID-19抗體療法獲得了美國食品和藥品管理局的緊急使用授權。